Tan, E. K. et al. Parkinson disease and the immune system—associations, mechanisms and therapeutics. Nat. Rev. Neurol. 16, 303–318 (2020).
Zhu, B., Yin, D., Zhao, H. & Zhang, L. The immunology of Parkinson’s disease. Semin. Immunopathol. 44, 659–672 (2022).
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R. & Foltynie, T. Progress towards therapies for disease modification in Parkinson’s disease. Lancet Neurol. 20, 559–572 (2021).
McGeer, P. L., Itagaki, S., Akiyama, H. & McGeer, E. G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24, 574–576 (1988).
Galiano-Landeira, J., Torra, A., Vila, M. & Bove, J. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson’s disease. Brain 143, 3717–3733 (2020).
Sulzer, D. et al. T cells from patients with Parkinson’s disease recognize alpha-synuclein peptides. Nature 546, 656–661 (2017).
Scott, K. M., Kouli, A., Yeoh, S. L., Clatworthy, M. R. & Williams-Gray, C. H. A systematic review and meta-analysis of alpha synuclein auto-antibodies in Parkinson’s disease. Front. Neurol. 9, 815 (2018).
Hamza, T. H. et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s disease. Nat. Genet. 42, 781–785 (2010).
Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091–1102 (2019).
Raj, T. et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 344, 519–523 (2014).
Gagliano, S. A. et al. Genomics implicates adaptive and innate immunity in Alzheimer’s and Parkinson’s diseases. Ann. Clin. Transl. Neurol. 3, 924–933 (2016).
Lu, Q. et al. Systematic tissue-specific functional annotation of the human genome highlights immune-related DNA elements for late-onset Alzheimer’s disease. PLoS Genet. 13, e1006933 (2017).
Andersen, M. S. et al. Heritability enrichment implicates microglia in Parkinson’s disease pathogenesis. Ann. Neurol. 89, 942–951 (2021).
Tansey, K. E., Cameron, D. & Hill, M. J. Genetic risk for Alzheimer’s disease is concentrated in specific macrophage and microglial transcriptional networks. Genome Med. 10, 14 (2018).
Navarro, E. et al. Dysregulation of mitochondrial and proteolysosomal genes in Parkinson’s disease myeloid cells. Nat. Aging 1, 850–863 (2021).
Cavalli, G. & Heard, E. Advances in epigenetics link genetics to the environment and disease. Nature 571, 489–499 (2019).
Hwang, J. Y., Aromolaran, K. A. & Zukin, R. S. The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat. Rev. Neurosci. 18, 347–361 (2017).
Song, H. et al. Epigenetic modification in Parkinson’s disease. Front. Cell Dev. Biol. 11, 1123621 (2023).
Pavlou, M. A. S. & Outeiro, T. F. Epigenetics in Parkinson’s disease. Adv. Exp. Med. Biol. 978, 363–390 (2017).
Kaut, O. et al. Epigenome-wide analysis of DNA methylation in Parkinson’s disease cortex. Life 12, 502 (2022).
Young, J. I. et al. Genome-wide brain DNA methylation analysis suggests epigenetic reprogramming in Parkinson disease. Neurol. Genet. 5, e342 (2019).
Masliah, E., Dumaop, W., Galasko, D. & Desplats, P. Distinctive patterns of DNA methylation associated with Parkinson disease: identification of concordant epigenetic changes in brain and peripheral blood leukocytes. Epigenetics 8, 1030–1038 (2013).
Pihlstrom, L. et al. Epigenome-wide association study of human frontal cortex identifies differential methylation in Lewy body pathology. Nat. Commun. 13, 4932 (2022).
Marshall, L. L. et al. Epigenomic analysis of Parkinson’s disease neurons identifies Tet2 loss as neuroprotective. Nat. Neurosci. 23, 1203–1214 (2020).
Kochmanski, J., Kuhn, N. C. & Bernstein, A. I. Parkinson’s disease-associated, sex-specific changes in DNA methylation at PARK7 (DJ-1), SLC17A6 (VGLUT2), PTPRN2 (IA-2beta), and NR4A2 (NURR1) in cortical neurons. NPJ Parkinsons Dis. 8, 120 (2022).
Moore, K., McKnight, A. J., Craig, D. & O’Neill, F. Epigenome-wide association study for Parkinson’s disease. Neuromol. Med 16, 845–855 (2014).
Chuang, Y. H. et al. Parkinson’s disease is associated with DNA methylation levels in human blood and saliva. Genome Med. 9, 76 (2017).
Henderson-Smith, A. et al. DNA methylation changes associated with Parkinson’s disease progression: outcomes from the first longitudinal genome-wide methylation analysis in blood. Epigenetics 14, 365–382 (2019).
Paul, K. C. et al. Immune system disruptions implicated in whole blood epigenome-wide association study of depression among Parkinson’s disease patients. Brain Behav. Immun. Health 26, 100530 (2022).
Vallerga, C. L. et al. Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson’s disease. Nat. Commun. 11, 1238 (2020).
Postuma, R. B. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov. Disord. 30, 1591–1601 (2015).
Graw, S., Henn, R., Thompson, J. A. & Koestler, D. C. pwrEWAS: a user-friendly tool for comprehensive power estimation for epigenome wide association studies (EWAS). BMC Bioinforma. 20, 218 (2019).
Breheny, P., Stromberg, A. & Lambert, J. P-value histograms: inference and diagnostics. High Throughput 7, 23 (2018).
Zhang, L. et al. Sex-specific DNA methylation differences in Alzheimer’s disease pathology. Acta Neuropathol. Commun. 9, 77 (2021).
Castro de Moura, M. et al. Epigenome-wide association study of COVID-19 severity with respiratory failure. EBioMedicine 66, 103339 (2021).
Bradic, M. et al. DNA methylation predicts the outcome of COVID-19 patients with acute respiratory distress syndrome. J. Transl. Med. 20, 526 (2022).
Gaunt, T. R. et al. Systematic identification of genetic influences on methylation across the human life course. Genome Biol. 17, 61 (2016).
Campagna, M. P. et al. Epigenome-wide association studies: current knowledge, strategies and recommendations. Clin. Epigenet. 13, 214 (2021).
Li, Y. I., Wong, G., Humphrey, J. & Raj, T. Prioritizing Parkinson’s disease genes using population-scale transcriptomic data. Nat. Commun. 10, 994 (2019).
Schmitt, I. et al. L-dopa increases alpha-synuclein DNA methylation in Parkinson’s disease patients in vivo and in vitro. Mov. Disord. 30, 1794–1801 (2015).
Gu, C. et al. The IFN-gamma-related long non-coding RNA signature predicts prognosis and indicates immune microenvironment infiltration in uterine corpus endometrial carcinoma. Front. Oncol. 12, 955979 (2022).
Sui, J. et al. Integrated analysis of long non-coding RNAassociated ceRNA network reveals potential lncRNA biomarkers in human lung adenocarcinoma. Int. J. Oncol. 49, 2023–2036 (2016).
Humayun, A. & Fornace, A. J. Jr. GADD45 in stress signaling, cell cycle control, and apoptosis. Adv. Exp. Med. Biol. 1360, 1–22 (2022).
Gao, Y. et al. The emerging role of Rab GTPases in the pathogenesis of Parkinson’s disease. Mov. Disord. 33, 196–207 (2018).
Waschbusch, D. et al. LRRK2 transport is regulated by its novel interacting partner Rab32. PLoS ONE 9, e111632 (2014).
McGrath, E., Waschbusch, D., Baker, B. M. & Khan, A. R. LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner via its armadillo domain. Small GTPases 12, 133–146 (2021).
Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607 (2004).
Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson’s disease. Neuron 44, 595–600 (2004).
Langston, R. G. et al. Association of a common genetic variant with Parkinson’s disease is mediated by microglia. Sci. Transl. Med. 14, eabp8869 (2022).
Kim, C. et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci. Transl. Med. 12, eaay0399 (2020).
Xu, E. et al. Pathological alpha-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. Mol. Neurodegener. 17, 7 (2022).
Stevens, C. H. et al. Reduced T helper and B lymphocytes in Parkinson’s disease. J. Neuroimmunol. 252, 95–99 (2012).
Horvath, S. & Ritz, B. R. Increased epigenetic age and granulocyte counts in the blood of Parkinson’s disease patients. Aging 7, 1130–1142 (2015).
Hannon, E., Weedon, M., Bray, N., O’Donovan, M. & Mill, J. Pleiotropic effects of trait-associated genetic variation on DNA methylation: utility for refining GWAS loci. Am. J. Hum. Genet. 100, 954–959 (2017).
Tsalenchuk, M., Gentleman, S. M. & Marzi, S. J. Linking environmental risk factors with epigenetic mechanisms in Parkinson’s disease. NPJ Parkinsons Dis. 9, 123 (2023).
Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics 30, 1363–1369 (2014).
Pidsley, R. et al. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genomics 14, 293 (2013).
Fortin, J. P. et al. Functional normalization of 450k methylation array data improves replication in large cancer studies. Genome Biol. 15, 503 (2014).
Chen, Y. A. et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 8, 203–209 (2013).
Chen, J. et al. CpGFilter: model-based CpG probe filtering with replicates for epigenome-wide association studies. Bioinformatics 32, 469–471 (2016).
Piehler, A. P., Grimholt, R. M., Ovstebo, R. & Berg, J. P. Gene expression results in lipopolysaccharide-stimulated monocytes depend significantly on the choice of reference genes. BMC Immunol. 11, 21 (2010).
Maess, M. B., Sendelbach, S. & Lorkowski, S. Selection of reliable reference genes during THP-1 monocyte differentiation into macrophages. BMC Mol. Biol. 11, 90 (2010).
Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101–1108 (2008).
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28, 882–883 (2012).
Leek, J. T. Asymptotic conditional singular value decomposition for high-dimensional genomic data. Biometrics 67, 344–352 (2011).
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
Mansell, G. et al. Guidance for DNA methylation studies: statistical insights from the Illumina EPIC array. BMC Genomics 20, 366 (2019).
Peters, T. J. et al. De novo identification of differentially methylated regions in the human genome. Epigenet. Chromatin 8, 6 (2015).
Phipson, B., Maksimovic, J. & Oshlack, A. missMethyl: an R package for analyzing data from Illumina’s HumanMethylation450 platform. Bioinformatics 32, 286–288 (2016).